Published on 12 Feb 2024 on Insider Monkey via Yahoo Finance
Cytokinetics, Incorporated (CYTK) Rose on Successful Clinical Trial
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. Small-cap stocks had excellent increases in the fourth quarter, following disappointing results in the third quarter. The Russell 2000 Growth Index (up 12.75%) fell behind the Russell 2000 Value Index (up 15.25%) for the second consecutive quarter. Small-cap companies performed well overall, with the Russell 2000 Growth Index (up 18.66%) outperforming the Russell 2000 Value Index (up 14.63%) for the year. In addition, you can check the top 5 holdings of the fund to know its best picks in 2023.
Carillon Eagle Small Cap Growth Fund featured stocks such as Cytokinetics, Incorporated (NASDAQ:CYTK) in its Q4 2023 investor letter. Headquartered in South San Francisco, California, Cytokinetics, Incorporated (NASDAQ:CYTK) is a biopharmaceutical company. On February 9, 2024, Cytokinetics, Incorporated (NASDAQ:CYTK) stock closed at $76.94 per share. One-month return of Cytokinetics, Incorporated (NASDAQ:CYTK) was -10.12%, and its shares gained 76.55% of their value over the last 52 weeks. Cytokinetics, Incorporated (NASDAQ:CYTK) has a market capitalization of $7.734 billion.
Carillon Eagle Small Cap Growth Fund stated the following regarding Cytokinetics, Incorporated (NASDAQ:CYTK) in its fourth quarter 2023 investor letter: